GlaxoSmithKline, Pfizer's HIV Treatment Meets Primary Endpoint in Trial
10 Julio 2019 - 01:54AM
Noticias Dow Jones
By Adria Calatayud
GlaxoSmithKline PLC (GSK.LN) said Wednesday that ViiV
Healthcare, its HIV venture with Pfizer Inc. (PFE), has met primary
endpoint in a phase 3 clinical trial.
The trial demonstrated the ability to control HIV with a
two-drug regimen of dolutegravir plus lamivudine in virally
suppressed patients switching from a three-drug regimen containing
tenofovir alafenamide fumarate, the U.K. pharmaceutical company
said.
The study was conducted to assess whether adults living with HIV
who had maintained viral suppression for at least six months on a
regimen of at least three drugs containing tenofovir alafenamide
fumarate were able to maintain similar rates of viral suppression
after switching to the two-drug regimen, Glaxo said.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
July 10, 2019 02:39 ET (06:39 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024